Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

Study Purpose

This phase III trial tests how well the addition of dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy works for treating children with newly diagnosed high-risk neuroblastoma. Dinutuximab is a monoclonal antibody that binds to a molecule called GD2, which is found on the surface of neuroblastoma cells, but is not present on many healthy or normal cells in the body. When dinutuximab binds to the neuroblastoma cells, it helps signal the immune system to kill the tumor cells. This helps the cells of the immune system kill the cancer cells, this is a type of immunotherapy. When chemotherapy and immunotherapy are given together, during the same treatment cycle, it is called chemoimmunotherapy. This clinical trial randomly assigns patients to receive either standard chemotherapy and surgery or chemoimmunotherapy (chemotherapy plus dinutuximab) and surgery during Induction therapy. Chemotherapy drugs administered during Induction include, cyclophosphamide, topotecan, cisplatin, etoposide, vincristine, and doxorubicin. These drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing or by stopping them from spreading. Upon completion of 5 cycles of Induction therapy, a disease evaluation is completed to determine how well the treatment worked. If the tumor responds to therapy, patients receive a tandem transplantation with stem cell rescue. If the tumor has little improvement or worsens, patients receive chemoimmunotherapy on Extended Induction. During Extended Induction, dinutuximab is given with irinotecan, temozolomide. Patients with a good response to therapy move on to Consolidation therapy, when very high doses of chemotherapy are given at two separate points to kill any remaining cancer cells. Following, transplant, radiation therapy is given to the site where the cancer originated (primary site) and to any other areas that are still active at the end of Induction. The final stage of therapy is Post-Consolidation. During Post-Consolidation, dinutuximab is given with isotretinoin, with the goal of maintaining the response achieved with the previous therapy. Adding dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy may be better at treating children with newly diagnosed high-risk neuroblastoma.

Recruitment Criteria

Accepts Healthy Volunteers Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms	No
Study Type An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes. An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes. Searching Both is inclusive of interventional and observational studies.	Interventional
Eligible Ages	N/A - 30 Years
Gender	All

More Inclusion & Exclusion Criteria

Inclusion Criteria:

- Patients must be enrolled on APEC14B1 and have consented to testing through the Molecular Characterization Initiative (MCI), prior to enrollment on ANBL2131.

- ≤ 30 years at the time of initial diagnosis with high-risk disease.

- * Must have a diagnosis of neuroblastoma (NBL) or ganglioneuroblastoma (nodular) verified by tumor pathology analysis or demonstration of clumps of tumor cells in bone marrow with elevated urinary catecholamines.

- Newly diagnosed, high risk neuroblastoma (HRNBL) defined as one of the following: - Any age with International Neuroblastoma Risk Group (INRG) Stage L2, MS, or M and MYCN amplification.

- Age ≥ 547 days and INRG stage M regardless of biologic features (clinical MYCN testing not required prior to enrollment) - Any age initially diagnosed with INRG Stage L1 MYCN amplified NBL who have progressed to stage M without systemic chemotherapy.

- Age ≥ 547 days of age initially diagnosed with INRG Stage L1, L2, or MS who have progressed to stage M without systemic chemotherapy (clinical MYCN testing not required prior to enrollment) - Patients must have a body surface area (BSA) ≥ 0.25 m^2.

- No prior anti-cancer therapy except as outlined below: - Patients initially recognized to have high-risk disease treated with topotecan/cyclophosphamide initiated on an emergent basis and within allowed timing, and with consent.

- Patients observed or treated with a single cycle of chemotherapy per a low or intermediate risk neuroblastoma regimen (e.g., as per ANBL0531, ANBL1232 or similar) for what initially appeared to be non-high-risk disease but subsequently found to meet the criteria.

- Patients who received localized emergency radiation to sites of life threatening or function-threatening disease prior to or immediately after establishment of the definitive diagnosis.

- Human immunodeficiency virus (HIV) -infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.

- A serum creatinine based on age/sex as follows: - 1 month to < 6 months: Male 0.4 mg/dL and female 0.4mg/dL.

- 6 months to < 1 year: Male 0.5 mg/dL and female 0.5 mg/dL.

- 1 to < 2 years: Male 0.6 mg/dL and female 0.6 mg/dL.

- 2 to < 6 years: Male 0.8 mg/dL and female 0.8 mg/dL.

- 6 to < 10 years: Male 1 mg/dL and female 1 mg/dL.

- 10 to < 13 years: Male 1.2 mg/dL and female 1.2 mg/dL.

- 13 to < 16 years: Male 1.5 mg/dL and female 1.4 mg/dL.

- ≥ 16 years: Male 1.7 mg/dL and female 1.4 mg/dL.

- The threshold creatinine values were derived from the Schwartz formula for estimating glomerular filtration rate (GFR) utilizing child length and stature data published by the Centers for Disease Control (CDC) - or a 24-hour urine creatinine clearance ≥ 70 mL/min/1.73 m^2 or.

- or a GFR ≥ 70 mL/min/1.73 m^2.

GFR must be performed using direct measurement with a nuclear blood sampling method or direct small molecule clearance method (iothalamate or other molecule per institutional standard)

- Note: Estimated GFR (eGFR) from serum creatinine, cystatin C or other estimates are not acceptable for determining eligibility.

- Total bilirubin ≤ 1.5 x upper limit of normal (ULN) for age.

- Serum glutamic pyruvic transaminase (SGPT) (Alanine aminotransferase [ALT]) ≤ 10 x ULN* - Note: For the purpose of this study, the ULN for SGPT (ALT) has been set to the value of 45 U/L.

- * Shortening fraction of ≥ 27% by echocardiogram, or.

- Ejection fraction of ≥ 50% by echocardiogram or radionuclide angiogram.

- Ability to tolerate Peripheral Blood Stem Cell (PBSC) collection: No known contraindication to PBSC collection.

Examples of contraindications might be a weight or size less than the collecting institution finds feasible, or a physical condition that would limit the ability of the child to undergo apheresis catheter placement (if necessary) and/or the apheresis procedure.

Exclusion Criteria:

- Patients who are 365-546 days of age with INRG Stage M and MYCN non-amplified NBL, irrespective of additional biologic features.

- Patients ≥ 547 days of age with INRG Stage L2, MYCN non-amplified NBL, regardless of additional biologic features.

- Patients with known bone marrow failure syndromes.

- Patients on chronic immunosuppressive medications (e.g., tacrolimus, cyclosporine, corticosteroids) for reasons other than prevention/treatment of allergic reactions and adrenal replacement therapy are not eligible.

Topical and inhaled corticosteroids are acceptable.

- Patients with a primary immunodeficiency syndrome who require ongoing immune globulin replacement therapy.

- Female patients who are pregnant since fetal toxicities and teratogenic effects have been noted for several of the study drugs.

A pregnancy test is required prior to enrollment for female patients of childbearing potential.

- Lactating females who plan to breastfeed their infants.

- Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their study participation.

- All patients and/or their parents or legal guardians must sign a written informed consent.

- All institutional, food and drug administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met

Trial Details

Trial ID: This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.	NCT06172296
Phase Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans. Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data. Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.	Phase 3
Lead Sponsor The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.	National Cancer Institute (NCI)
Principal Investigator The person who is responsible for the scientific and technical direction of the entire clinical study.	Sara M Federico
Principal Investigator Affiliation	Children's Oncology Group
Agency Class Category of organization(s) involved as sponsor (and collaborator) supporting the trial.	NIH
Overall Status	Recruiting
Countries	Australia, Canada, New Zealand, United States
Conditions The disease, disorder, syndrome, illness, or injury that is being studied.	Ganglioneuroblastoma, Nodular, Neuroblastoma

Additional Details

PRIMARY OBJECTIVE:

I. To determine if the event-free survival (EFS) of patients with newly diagnosed high-risk neuroblastoma assigned to early chemoimmunotherapy during Induction differs from that of patients who are not assigned to treatment that includes early chemoimmunotherapy.

SECONDARY OBJECTIVES:

I. To determine if early chemoimmunotherapy during Induction therapy improves end of Induction (EOI) response rates and overall survival (OS) for patients with newly diagnosed high-risk neuroblastoma.

II. To determine response rates, EFS, and OS following an Extended Induction regimen with chemoimmunotherapy in patients with progressive disease or a poor response to Induction therapy.

III. To compare the toxicities experienced by patients treated with chemoimmunotherapy during Induction versus those experienced by patients treated with standard Induction and to describe toxicities experienced during Extended Induction.

IV. To determine GD2 expression on tumor tissue and tumor cells in bone marrow and assess for associations with response and outcome.

EXPLORATORY OBJECTIVES:

I. To describe the association between tumor and host factors and outcomes in patients receiving protocol therapy.

II. To evaluate circulating biomarkers and markers of minimal residual disease at baseline and during therapy, and assess for associations with response and outcome.

III. To compare patterns of failure between patients treated with and without dinutuximab during induction.

IV. To determine the effect of telomere maintenance mechanisms on end of Induction response rates, EFS, and OS.

V. To explore the impact of high-risk neuroblastoma (HRNBL) and its therapy, including the addition of dinutuximab to Induction chemotherapy, on functional and quality of life outcomes in patients with HRNBL, as measured by caregiver (parent/legal guardian) and patient questionnaires.

VI. To describe the adequacy of diagnostic biopsy specimens, including those obtained by percutaneous core needle biopsy.

VII. To explore the associations between family-reported adverse social determinants of health and both clinical outcomes and biology.

VIII. To develop and validate deep learning predictors of Induction response based on diagnostic MIBG scans.

(Imaging Objective)

IX. To compare institutional versus central determination of overall response, individual response components (primary tumor, soft tissue and bone metastatic disease, and bone marrow metastatic disease), and poor end of induction response (PEIR) and good end of induction response (GEIR) determination.

(Imaging Objective)

X. To describe late toxicities (including impaired organ function, neuropsychiatric toxicity, and incidence of secondary malignancy) in patients treated with dinutuximab during Induction or Extended Induction to late toxicities in patients who have not received dinutuximab during these phases of therapy.

XI. To evaluate whether reduced dose radiotherapy to the primary site clinical target volume (CTV) in patients with complete response of the primary site at EOI results in comparable local control relative to historical cohorts. XII. To compare post-transplant complications between treatment arms, and assess for associations with outcome. XIII. To assess for associations between EOI response (including good end of Induction response [GEIR] and poor end of Induction response [PEIR]) and individual response components (primary tumor, soft tissue and bone metastatic disease, and bone marrow metastatic disease) with outcome (EFS and OS). XIV. To describe and compare the changes in image-defined risk factors (IDRFs) between patients treated with and without dinutuximab during Induction and associate with surgical outcomes and local failure rates following primary tumor resection. XV. To bank serial samples of blood, bone marrow, and tumor tissue for future research. OUTLINE: Patients receive Induction cycle 1 and are then randomized to 1 of 2 treatment arms. INDUCTION CYCLE 1: Patients receive cyclophosphamide intravenously (IV) over 30 minutes and topotecan IV over 30 minutes on days 1-5 in the absence of unacceptable toxicity. ARM A: INDUCTION CYCLES 2-5: Patients receive cyclophosphamide IV over 30 minutes and topotecan IV over 30 minutes on days 1-5 of cycle 2 in the absence of unacceptable toxicity. Patients then undergo stem cell harvest via apheresis. Patients then receive cisplatin IV over 4 hours and etoposide IV over 2 hours on days 1-3 of cycles 3 and 5, and vincristine IV on day 1, doxorubicin IV over 15 minutes, and cyclophosphamide IV over 1 hour on days 1-2 of cycle 4 in the absence of unacceptable toxicity. Patients undergo primary tumor resection after Induction cycle 4 or 5. Following Induction cycle 5, patients undergo testing to determine response to Induction therapy. Patients with a good tumor response proceed to Consolidation, while patients with a poor tumor response proceed to Extended Induction. EXTENDED INDUCTION: Patients with a poor tumor response or progression during Induction receive temozolomide orally (PO), via nasogastric tube (NG), or via gastric tube (G-tube) on days 1-5, irinotecan IV over 90 minutes on days 1-5, and dinutuximab IV over 10 hours. Treatment repeats every 21 days for up to a maximum of 6 cycles in the absence of disease progression or unacceptable toxicity. If at any time during Extended Induction testing shows a good tumor response, patients proceed to Consolidation. If after 6 cycles of Extended Induction or if at any time progression is noted, patients are removed from the study. CONSOLIDATION: Patients undergo two autologous hematopoietic stem cell transplantations (HSCTs) during Consolidation. Patients receive thiotepa IV over 2 hours on days -7 to -5 and cyclophosphamide IV over 1 hour on days -5 to -2 during HSCT 1. Patients then receive stem cell infusion IV on day 0. Between 6 and 10 weeks after stem cell infusion, patients receive melphalan IV over 30 minutes on days -7 to -5, etoposide IV over 24 hours on days -7 to -4, and carboplatin over 24 hours on days -7 to -4 during HSCT 2. Patients receive stem cell infusion IV on day 0. Between day +42 and day +80 after HSCT 2. Patients receive radiation daily for 12 treatments in the absence of disease progression or unacceptable toxicity. POST CONSOLIDATION: Patients receive dinutuximab IV over 10 hours on days 4-7 and isotretinoin PO twice daily (BID) on days 11-24 of cycles 1-5. Treatment repeats every 28 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive isotretinoin PO BID on days 15-28 for 1 additional cycle, cycle 6. Patients undergo blood and urine sample collection, echocardiogram (ECHO) or multigated acquisition scan (MUGA), bone marrow aspiration and/or biopsy, computed tomography (CT) scan, magnetic resonance imaging (MRI), iodine-123 meta-iodobenzylguanidine (I-MIBG) scan and possible fluorodeoxyglucose position emission tomography (FDG-PET) scan throughout the study. ARM B: INDUCTION CYCLES 2-5: Patients receive cyclophosphamide IV over 30 minutes, topotecan IV over 30 minutes on days 1-5, and dinutuximab IV over 10 hours on days 2-5 of cycle 2 in the absence of unacceptable toxicity. Patients then undergo stem cell harvest via apheresis. Patients receive cisplatin IV over 4 hours and etoposide IV over 2 hours on days 1-3 and dinutuximab IV over 10 hours on days 2-5 of cycles 3 and 5, and vincristine IV on day 1, doxorubicin IV over 15 minutes, and cyclophosphamide IV over 1 hour on days 1-2, and dinutuximab IV over 10 hours on days 2-5 of cycle 4 in the absence of unacceptable toxicity. Patients undergo primary tumor resection after Induction cycle 4 or 5. Following Induction cycle 5, patients undergo testing to determine response to Induction therapy. Patients with a good tumor response proceed to Consolidation, while patients with a poor tumor response proceed to Extended Induction. EXTENDED INDUCTION: Patients with a poor tumor response or progression during Induction receive temozolomide PO, via NG tube, or via G-tube on days 1-5, irinotecan IV over 90 minutes on days 1-5, and dinutuximab IV over 10 hours. Treatment repeats every 21 days for up to a maximum of 6 cycles in the absence of disease progression or unacceptable toxicity. If at any time during Extended Induction testing shows a good tumor response, patients proceed to Consolidation. If after 6 cycles of Extended Induction or if at any time progression is noted, patients are removed from the study. CONSOLIDATION: Patients undergo two autologous HSCTs during Consolidation. Patients receive thiotepa IV over 2 hours on days -7 to -5 and cyclophosphamide IV over 1 hour on days -5 to -2 during HSCT 1. Patients then receive stem cell infusion IV on day 0. Between 6 and 10 weeks after stem cell infusion patients receive melphalan IV over 30 minutes on days -7 to -5, etoposide IV over 24 hours on days -7 to -4, and carboplatin over 24 hours on days -7 to -4 during HSCT 2. Patients receive stem cell infusion IV on day 0. Between day +42 and day +80 after HSCT 2, patients receive radiation daily for 12 treatments in the absence of disease progression or unacceptable toxicity. POST CONSOLIDATION: Patients receive dinutuximab IV over 10 hours on days 4-7 and isotretinoin PO BID on days 11-24 of cycles 1-5. Treatment repeats every 28 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive isotretinoin PO BID on days 15-28 for 1 additional cycle, cycle 6. Patients undergo blood and urine sample collection, ECHO or MUGA, bone marrow aspiration and/or biopsy, CT scan, MRI, I-MIBG scan and possible FDG-PET scan throughout the study. After completion of study treatment, patients are followed up at 3, 6, 9,12, 15, 18, 24, 30, 36, 42, 48, 54, and 60 months and then periodically for up to 10 years from enrollment.

Arms & Interventions

Arms

Active Comparator: Arm A (SOC treatment)

See detailed description

Experimental: Arm B (Dinutuximab in induction)

See detailed description

Interventions

Procedure: - Biospecimen Collection

Undergo blood and urine sample collection

Procedure: - Bone Marrow Aspiration

Undergo bone marrow aspiration

Procedure: - Bone Marrow Biopsy

Undergo bone marrow biopsy

Drug: - Carboplatin

Given IV

Drug: - Cisplatin

Given IV

Procedure: - Computed Tomography

Undergo CT scan

Drug: - Cyclophosphamide

Given IV

Biological: - Dinutuximab

Given IV

Drug: - Doxorubicin

Given IV

Procedure: - Echocardiography Test

Undergo ECHO

Drug: - Etoposide

Given IV

Procedure: - FDG-Positron Emission Tomography and Computed Tomography Scan

Undergo FDG PET

Procedure: - Hematopoietic Cell Transplantation

Undergo stem cell infusion

Drug: - Irinotecan

Given IV

Drug: - Isotretinoin

Given PO

Procedure: - Leukapheresis

Undergo apheresis

Procedure: - Magnetic Resonance Imaging

Undergo MRI

Drug: - Melphalan

Given IV

Procedure: - Multigated Acquisition Scan

Undergo MUGA

Radiation: - Radiation Therapy

Undergo radiation therapy

Procedure: - Radionuclide Imaging

Undergo I-MIBG scan

Other: - Survey Administration

Ancillary studies

Drug: - Temozolomide

Given PO or via NG or G tube

Drug: - Thiotepa

Given IV

Drug: - Topotecan

Given IV

Procedure: - Tumor Resection

Undergo tumor resection surgery

Drug: - Vincristine

Given IV

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

Children's Hospital of Alabama, Birmingham, Alabama

Status

Recruiting

Address

Children's Hospital of Alabama

Birmingham, Alabama, 35233

Site Contact

Site Public Contact

[email protected]

205-638-9285

USA Health Strada Patient Care Center, Mobile, Alabama

Status

Recruiting

Address

USA Health Strada Patient Care Center

Mobile, Alabama, 36604

Site Contact

Site Public Contact

800-388-8721

Phoenix Childrens Hospital, Phoenix, Arizona

Status

Recruiting

Address

Phoenix Childrens Hospital

Phoenix, Arizona, 85016

Site Contact

Site Public Contact

602-546-0920

Tucson, Arizona

Status

Recruiting

Address

Banner University Medical Center - Tucson

Tucson, Arizona, 85719

Site Contact

Site Public Contact

[email protected]

Arkansas Children's Hospital, Little Rock, Arkansas

Status

Recruiting

Address

Arkansas Children's Hospital

Little Rock, Arkansas, 72202-3591

Site Contact

Site Public Contact

501-364-7373

Kaiser Permanente Downey Medical Center, Downey, California

Status

Recruiting

Address

Kaiser Permanente Downey Medical Center

Downey, California, 90242

Site Contact

Site Public Contact

626-564-3455

City of Hope Comprehensive Cancer Center, Duarte, California

Status

Recruiting

Address

City of Hope Comprehensive Cancer Center

Duarte, California, 91010

Site Contact

Site Public Contact

[email protected]

800-826-4673

Loma Linda University Medical Center, Loma Linda, California

Status

Recruiting

Address

Loma Linda University Medical Center

Loma Linda, California, 92354

Site Contact

Site Public Contact

909-558-4050

Long Beach, California

Status

Recruiting

Address

Miller Children's and Women's Hospital Long Beach

Long Beach, California, 90806

Site Contact

Site Public Contact

562-933-5600

Children's Hospital Los Angeles, Los Angeles, California

Status

Recruiting

Address

Children's Hospital Los Angeles

Los Angeles, California, 90027

Site Contact

Site Public Contact

323-361-4110

Cedars Sinai Medical Center, Los Angeles, California

Status

Recruiting

Address

Cedars Sinai Medical Center

Los Angeles, California, 90048

Site Contact

Site Public Contact

310-423-8965

Mattel Children's Hospital UCLA, Los Angeles, California

Status

Recruiting

Address

Mattel Children's Hospital UCLA

Los Angeles, California, 90095

Site Contact

Site Public Contact

310-825-6708

Valley Children's Hospital, Madera, California

Status

Recruiting

Address

Valley Children's Hospital

Madera, California, 93636

Site Contact

Site Public Contact

[email protected]

559-353-3000

UCSF Benioff Children's Hospital Oakland, Oakland, California

Status

Recruiting

Address

UCSF Benioff Children's Hospital Oakland

Oakland, California, 94609

Site Contact

Site Public Contact

[email protected]

510-428-3264

Kaiser Permanente-Oakland, Oakland, California

Status

Recruiting

Address

Kaiser Permanente-Oakland

Oakland, California, 94611

Site Contact

Site Public Contact

[email protected]

877-642-4691

Children's Hospital of Orange County, Orange, California

Status

Recruiting

Address

Children's Hospital of Orange County

Orange, California, 92868

Site Contact

Site Public Contact

[email protected]

714-509-8646

Palo Alto, California

Status

Recruiting

Address

Lucile Packard Children's Hospital Stanford University

Palo Alto, California, 94304

Site Contact

Site Public Contact

[email protected]

800-694-0012

Sacramento, California

Status

Recruiting

Address

University of California Davis Comprehensive Cancer Center

Sacramento, California, 95817

Site Contact

Site Public Contact

916-734-3089

UCSF Medical Center-Mission Bay, San Francisco, California

Status

Recruiting

Address

UCSF Medical Center-Mission Bay

San Francisco, California, 94158

Site Contact

Site Public Contact

[email protected]

877-827-3222

Children's Hospital Colorado, Aurora, Colorado

Status

Recruiting

Address

Children's Hospital Colorado

Aurora, Colorado, 80045

Site Contact

Site Public Contact

[email protected]

303-764-5056

Connecticut Children's Medical Center, Hartford, Connecticut

Status

Recruiting

Address

Connecticut Children's Medical Center

Hartford, Connecticut, 06106

Site Contact

Site Public Contact

860-545-9981

Yale University, New Haven, Connecticut

Status

Recruiting

Address

Yale University

New Haven, Connecticut, 06520

Site Contact

Site Public Contact

[email protected]

203-785-5702

Alfred I duPont Hospital for Children, Wilmington, Delaware

Status

Recruiting

Address

Alfred I duPont Hospital for Children

Wilmington, Delaware, 19803

Site Contact

Site Public Contact

[email protected]

302-651-5572

Children's National Medical Center, Washington, District of Columbia

Status

Recruiting

Address

Children's National Medical Center

Washington, District of Columbia, 20010

Site Contact

Site Public Contact

[email protected]

202-476-2800

Fort Myers, Florida

Status

Recruiting

Address

Golisano Children's Hospital of Southwest Florida

Fort Myers, Florida, 33908

Site Contact

Site Public Contact

[email protected]

239-343-5333

Gainesville, Florida

Status

Suspended

Address

University of Florida Health Science Center - Gainesville

Gainesville, Florida, 32610

Hollywood, Florida

Status

Recruiting

Address

Memorial Regional Hospital/Joe DiMaggio Children's Hospital

Hollywood, Florida, 33021

Site Contact

Site Public Contact

[email protected]

954-265-1847

Nemours Children's Clinic-Jacksonville, Jacksonville, Florida

Status

Recruiting

Address

Nemours Children's Clinic-Jacksonville

Jacksonville, Florida, 32207

Site Contact

Site Public Contact

[email protected]

302-651-5572

Miami, Florida

Status

Recruiting

Address

University of Miami Miller School of Medicine-Sylvester Cancer Center

Miami, Florida, 33136

Site Contact

Site Public Contact

305-243-2647

Nicklaus Children's Hospital, Miami, Florida

Status

Recruiting

Address

Nicklaus Children's Hospital

Miami, Florida, 33155

Site Contact

Site Public Contact

888-624-2778

AdventHealth Orlando, Orlando, Florida

Status

Recruiting

Address

AdventHealth Orlando

Orlando, Florida, 32803

Site Contact

Site Public Contact

[email protected]

407-303-2090

Arnold Palmer Hospital for Children, Orlando, Florida

Status

Recruiting

Address

Arnold Palmer Hospital for Children

Orlando, Florida, 32806

Site Contact

Site Public Contact

[email protected]

321-841-5357

Nemours Children's Hospital, Orlando, Florida

Status

Recruiting

Address

Nemours Children's Hospital

Orlando, Florida, 32827

Site Contact

Site Public Contact

[email protected]

302-651-5572

Johns Hopkins All Children's Hospital, Saint Petersburg, Florida

Status

Recruiting

Address

Johns Hopkins All Children's Hospital

Saint Petersburg, Florida, 33701

Site Contact

Site Public Contact

[email protected]

727-767-4784

Saint Mary's Medical Center, West Palm Beach, Florida

Status

Recruiting

Address

Saint Mary's Medical Center

West Palm Beach, Florida, 33407

Site Contact

Site Public Contact

561-822-4745

Atlanta, Georgia

Status

Recruiting

Address

Children's Healthcare of Atlanta - Arthur M Blank Hospital

Atlanta, Georgia, 30329

Site Contact

Site Public Contact

[email protected]

404-785-2025

Lurie Children's Hospital-Chicago, Chicago, Illinois

Status

Recruiting

Address

Lurie Children's Hospital-Chicago

Chicago, Illinois, 60611

Site Contact

Site Public Contact

773-880-4562

University of Illinois, Chicago, Illinois

Status

Recruiting

Address

University of Illinois

Chicago, Illinois, 60612

Site Contact

Site Public Contact

312-355-3046

Chicago, Illinois

Status

Recruiting

Address

University of Chicago Comprehensive Cancer Center

Chicago, Illinois, 60637

Site Contact

Site Public Contact

[email protected]

773-702-8222

Advocate Children's Hospital-Oak Lawn, Oak Lawn, Illinois

Status

Recruiting

Address

Advocate Children's Hospital-Oak Lawn

Oak Lawn, Illinois, 60453

Site Contact

Site Public Contact

847-723-7570

Advocate Children's Hospital-Park Ridge, Park Ridge, Illinois

Status

Recruiting

Address

Advocate Children's Hospital-Park Ridge

Park Ridge, Illinois, 60068

Site Contact

Site Public Contact

[email protected]

Saint Jude Midwest Affiliate, Peoria, Illinois

Status

Recruiting

Address

Saint Jude Midwest Affiliate

Peoria, Illinois, 61637

Site Contact

Site Public Contact

888-226-4343

Springfield, Illinois

Status

Recruiting

Address

Southern Illinois University School of Medicine

Springfield, Illinois, 62702

Site Contact

Site Public Contact

217-545-7929

Riley Hospital for Children, Indianapolis, Indiana

Status

Recruiting

Address

Riley Hospital for Children

Indianapolis, Indiana, 46202

Site Contact

Site Public Contact

800-248-1199

Blank Children's Hospital, Des Moines, Iowa

Status

Recruiting

Address

Blank Children's Hospital

Des Moines, Iowa, 50309

Site Contact

Site Public Contact

[email protected]

515-241-8912

Iowa City, Iowa

Status

Recruiting

Address

University of Iowa/Holden Comprehensive Cancer Center

Iowa City, Iowa, 52242

Site Contact

Site Public Contact

800-237-1225

Wesley Medical Center, Wichita, Kansas

Status

Recruiting

Address

Wesley Medical Center

Wichita, Kansas, 67214

Site Contact

Site Public Contact

[email protected]

316-962-7802

Lexington, Kentucky

Status

Recruiting

Address

University of Kentucky/Markey Cancer Center

Lexington, Kentucky, 40536

Site Contact

Site Public Contact

859-257-3379

Children's Hospital New Orleans, New Orleans, Louisiana

Status

Recruiting

Address

Children's Hospital New Orleans

New Orleans, Louisiana, 70118

Site Contact

Site Public Contact

[email protected]

Eastern Maine Medical Center, Bangor, Maine

Status

Recruiting

Address

Eastern Maine Medical Center

Bangor, Maine, 04401

Site Contact

Site Public Contact

207-973-4274

Maine Children's Cancer Program, Scarborough, Maine

Status

Recruiting

Address

Maine Children's Cancer Program

Scarborough, Maine, 04074

Site Contact

Site Public Contact

[email protected]

207-396-8670

Sinai Hospital of Baltimore, Baltimore, Maryland

Status

Recruiting

Address

Sinai Hospital of Baltimore

Baltimore, Maryland, 21215

Site Contact

Site Public Contact

[email protected]

410-601-6120

Baltimore, Maryland

Status

Recruiting

Address

Johns Hopkins University/Sidney Kimmel Cancer Center

Baltimore, Maryland, 21287

Site Contact

Site Public Contact

[email protected]

410-955-8804

Dana-Farber Cancer Institute, Boston, Massachusetts

Status

Recruiting

Address

Dana-Farber Cancer Institute

Boston, Massachusetts, 02215

Site Contact

Site Public Contact

877-442-3324

C S Mott Children's Hospital, Ann Arbor, Michigan

Status

Recruiting

Address

C S Mott Children's Hospital

Ann Arbor, Michigan, 48109

Site Contact

Site Public Contact

800-865-1125

Children's Hospital of Michigan, Detroit, Michigan

Status

Recruiting

Address

Children's Hospital of Michigan

Detroit, Michigan, 48201

Site Contact

Site Public Contact

[email protected]

Grand Rapids, Michigan

Status

Recruiting

Address

Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital

Grand Rapids, Michigan, 49503

Site Contact

Site Public Contact

[email protected]

616-267-1925

Bronson Methodist Hospital, Kalamazoo, Michigan

Status

Suspended

Address

Bronson Methodist Hospital

Kalamazoo, Michigan, 49007

Corewell Health Children's, Royal Oak, Michigan

Status

Recruiting

Address

Corewell Health Children's

Royal Oak, Michigan, 48073

Site Contact

Site Public Contact

248-551-7695

Minneapolis, Minnesota

Status

Recruiting

Address

Children's Hospitals and Clinics of Minnesota - Minneapolis

Minneapolis, Minnesota, 55404

Site Contact

Site Public Contact

[email protected]

612-813-5913

Minneapolis, Minnesota

Status

Recruiting

Address

University of Minnesota/Masonic Cancer Center

Minneapolis, Minnesota, 55455

Site Contact

Site Public Contact

612-624-2620

Mayo Clinic in Rochester, Rochester, Minnesota

Status

Recruiting

Address

Mayo Clinic in Rochester

Rochester, Minnesota, 55905

Site Contact

Site Public Contact

855-776-0015

University of Mississippi Medical Center, Jackson, Mississippi

Status

Recruiting

Address

University of Mississippi Medical Center

Jackson, Mississippi, 39216

Site Contact

Site Public Contact

601-815-6700

Children's Mercy Hospitals and Clinics, Kansas City, Missouri

Status

Recruiting

Address

Children's Mercy Hospitals and Clinics

Kansas City, Missouri, 64108

Site Contact

Site Public Contact

[email protected]

816-302-6808

Washington University School of Medicine, Saint Louis, Missouri

Status

Recruiting

Address

Washington University School of Medicine

Saint Louis, Missouri, 63110

Site Contact

Site Public Contact

[email protected]

800-600-3606

Mercy Hospital Saint Louis, Saint Louis, Missouri

Status

Recruiting

Address

Mercy Hospital Saint Louis

Saint Louis, Missouri, 63141

Site Contact

Site Public Contact

314-251-7066

Omaha, Nebraska

Status

Recruiting

Address

Children's Hospital and Medical Center of Omaha

Omaha, Nebraska, 68114

Site Contact

Site Public Contact

402-955-3949

University of Nebraska Medical Center, Omaha, Nebraska

Status

Recruiting

Address

University of Nebraska Medical Center

Omaha, Nebraska, 68198

Site Contact

Site Public Contact

[email protected]

402-559-6941

Lebanon, New Hampshire

Status

Recruiting

Address

Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center

Lebanon, New Hampshire, 03756

Site Contact

Site Public Contact

[email protected]

800-639-6918

Hackensack University Medical Center, Hackensack, New Jersey

Status

Recruiting

Address

Hackensack University Medical Center

Hackensack, New Jersey, 07601

Site Contact

Site Public Contact

551-996-2897

New Brunswick, New Jersey

Status

Recruiting

Address

Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital

New Brunswick, New Jersey, 08903

Site Contact

Site Public Contact

732-235-8675

Saint Joseph's Regional Medical Center, Paterson, New Jersey

Status

Recruiting

Address

Saint Joseph's Regional Medical Center

Paterson, New Jersey, 07503

Site Contact

Site Public Contact

[email protected]

973-754-2207

Albany Medical Center, Albany, New York

Status

Recruiting

Address

Albany Medical Center

Albany, New York, 12208

Site Contact

Site Public Contact

518-262-5513

Montefiore Medical Center - Moses Campus, Bronx, New York

Status

Recruiting

Address

Montefiore Medical Center - Moses Campus

Bronx, New York, 10467

Site Contact

Site Public Contact

[email protected]

718-379-6866

Roswell Park Cancer Institute, Buffalo, New York

Status

Recruiting

Address

Roswell Park Cancer Institute

Buffalo, New York, 14263

Site Contact

Site Public Contact

[email protected]

800-767-9355

NYU Langone Hospital - Long Island, Mineola, New York

Status

Recruiting

Address

NYU Langone Hospital - Long Island

Mineola, New York, 11501

Site Contact

Site Public Contact

[email protected]

212-263-4432

New Hyde Park, New York

Status

Recruiting

Address

The Steven and Alexandra Cohen Children's Medical Center of New York

New Hyde Park, New York, 11040

Site Contact

Site Public Contact

718-470-3460

New York, New York

Status

Recruiting

Address

NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center

New York, New York, 10032

Site Contact

Site Public Contact

[email protected]

212-342-5162

New York Medical College, Valhalla, New York

Status

Recruiting

Address

New York Medical College

Valhalla, New York, 10595

Site Contact

Site Public Contact

914-594-3794

Mission Hospital, Asheville, North Carolina

Status

Recruiting

Address

Mission Hospital

Asheville, North Carolina, 28801

Site Contact

Site Public Contact

[email protected]

828-213-7055

Chapel Hill, North Carolina

Status

Recruiting

Address

UNC Lineberger Comprehensive Cancer Center

Chapel Hill, North Carolina, 27599

Site Contact

Site Public Contact

[email protected]

877-668-0683

Charlotte, North Carolina

Status

Recruiting

Address

Carolinas Medical Center/Levine Cancer Institute

Charlotte, North Carolina, 28203

Site Contact

Site Public Contact

800-804-9376

Duke University Medical Center, Durham, North Carolina

Status

Recruiting

Address

Duke University Medical Center

Durham, North Carolina, 27710

Site Contact

Site Public Contact

888-275-3853

East Carolina University, Greenville, North Carolina

Status

Recruiting

Address

East Carolina University

Greenville, North Carolina, 27834

Site Contact

Site Public Contact

[email protected]

252-744-1015

Wake Forest University Health Sciences, Winston-Salem, North Carolina

Status

Recruiting

Address

Wake Forest University Health Sciences

Winston-Salem, North Carolina, 27157

Site Contact

Site Public Contact

336-713-6771

Sanford Broadway Medical Center, Fargo, North Dakota

Status

Recruiting

Address

Sanford Broadway Medical Center

Fargo, North Dakota, 58122

Site Contact

Site Public Contact

[email protected]

701-323-5760

Akron, Ohio

Status

Recruiting

Address

Children's Hospital Medical Center of Akron

Akron, Ohio, 44308

Site Contact

Site Public Contact

330-543-3193

Cincinnati, Ohio

Status

Recruiting

Address

Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, 45229

Site Contact

Site Public Contact

[email protected]

513-636-2799

Rainbow Babies and Childrens Hospital, Cleveland, Ohio

Status

Recruiting

Address

Rainbow Babies and Childrens Hospital

Cleveland, Ohio, 44106

Site Contact

Site Public Contact

216-844-5437

Cleveland Clinic Foundation, Cleveland, Ohio

Status

Recruiting

Address

Cleveland Clinic Foundation

Cleveland, Ohio, 44195

Site Contact

Site Public Contact

[email protected]

866-223-8100

Nationwide Children's Hospital, Columbus, Ohio

Status

Recruiting

Address

Nationwide Children's Hospital

Columbus, Ohio, 43205

Site Contact

Site Public Contact

[email protected]

614-722-6039

Dayton Children's Hospital, Dayton, Ohio

Status

Recruiting

Address

Dayton Children's Hospital

Dayton, Ohio, 45404

Site Contact

Site Public Contact

800-228-4055

Toledo, Ohio

Status

Recruiting

Address

ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital

Toledo, Ohio, 43606

Site Contact

Site Public Contact

[email protected]

419-824-1842

Oklahoma City, Oklahoma

Status

Recruiting

Address

University of Oklahoma Health Sciences Center

Oklahoma City, Oklahoma, 73104

Site Contact

Site Public Contact

[email protected]

405-271-8777

Legacy Emanuel Children's Hospital, Portland, Oregon

Status

Recruiting

Address

Legacy Emanuel Children's Hospital

Portland, Oregon, 97227

Site Contact

Site Public Contact

503-413-2560

Geisinger Medical Center, Danville, Pennsylvania

Status

Recruiting

Address

Geisinger Medical Center

Danville, Pennsylvania, 17822

Site Contact

Site Public Contact

[email protected]

570-271-5251

Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

Status

Recruiting

Address

Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, 19104

Site Contact

Site Public Contact

[email protected]

267-425-5544

Philadelphia, Pennsylvania

Status

Recruiting

Address

Saint Christopher's Hospital for Children

Philadelphia, Pennsylvania, 19134

Site Contact

Site Public Contact

215-427-8991

Pittsburgh, Pennsylvania

Status

Recruiting

Address

Children's Hospital of Pittsburgh of UPMC

Pittsburgh, Pennsylvania, 15224

Site Contact

Site Public Contact

[email protected]

412-692-8570

Rhode Island Hospital, Providence, Rhode Island

Status

Recruiting

Address

Rhode Island Hospital

Providence, Rhode Island, 02903

Site Contact

Site Public Contact

401-444-1488

Medical University of South Carolina, Charleston, South Carolina

Status

Recruiting

Address

Medical University of South Carolina

Charleston, South Carolina, 29425

Site Contact

Site Public Contact

[email protected]

843-792-9321

Prisma Health Richland Hospital, Columbia, South Carolina

Status

Recruiting

Address

Prisma Health Richland Hospital

Columbia, South Carolina, 29203

Site Contact

Site Public Contact

864-241-6251

BI-LO Charities Children's Cancer Center, Greenville, South Carolina

Status

Recruiting

Address

BI-LO Charities Children's Cancer Center

Greenville, South Carolina, 29605

Site Contact

Site Public Contact

864-241-6251

Sanford USD Medical Center - Sioux Falls, Sioux Falls, South Dakota

Status

Recruiting

Address

Sanford USD Medical Center - Sioux Falls

Sioux Falls, South Dakota, 57117-5134

Site Contact

Site Public Contact

[email protected]

605-312-3320

East Tennessee Childrens Hospital, Knoxville, Tennessee

Status

Recruiting

Address

East Tennessee Childrens Hospital

Knoxville, Tennessee, 37916

Site Contact

Site Public Contact

865-541-8266

Saint Jude Children's Research Hospital, Memphis, Tennessee

Status

Recruiting

Address

Saint Jude Children's Research Hospital

Memphis, Tennessee, 38105

Site Contact

Site Public Contact

[email protected]

888-226-4343

Nashville, Tennessee

Status

Recruiting

Address

The Children's Hospital at TriStar Centennial

Nashville, Tennessee, 37203

Site Contact

Site Public Contact

615-342-1919

Nashville, Tennessee

Status

Suspended

Address

Vanderbilt University/Ingram Cancer Center

Nashville, Tennessee, 37232

Austin, Texas

Status

Recruiting

Address

Dell Children's Medical Center of Central Texas

Austin, Texas, 78723

Site Contact

Site Public Contact

[email protected]

512-628-1902

Driscoll Children's Hospital, Corpus Christi, Texas

Status

Recruiting

Address

Driscoll Children's Hospital

Corpus Christi, Texas, 78411

Site Contact

Site Public Contact

[email protected]

361-694-5311

Medical City Dallas Hospital, Dallas, Texas

Status

Recruiting

Address

Medical City Dallas Hospital

Dallas, Texas, 75230

Site Contact

Site Public Contact

972-566-5588

Dallas, Texas

Status

Recruiting

Address

UT Southwestern/Simmons Cancer Center-Dallas

Dallas, Texas, 75390

Site Contact

Site Public Contact

[email protected]

214-648-7097

El Paso Children's Hospital, El Paso, Texas

Status

Recruiting

Address

El Paso Children's Hospital

El Paso, Texas, 79905

Site Contact

Site Public Contact

[email protected]

915-298-5444

Cook Children's Medical Center, Fort Worth, Texas

Status

Recruiting

Address

Cook Children's Medical Center

Fort Worth, Texas, 76104

Site Contact

Site Public Contact

[email protected]

682-885-2103

Houston, Texas

Status

Recruiting

Address

Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center

Houston, Texas, 77030

Site Contact

Site Public Contact

[email protected]

713-798-1354

M D Anderson Cancer Center, Houston, Texas

Status

Recruiting

Address

M D Anderson Cancer Center

Houston, Texas, 77030

Site Contact

Site Public Contact

[email protected]

877-632-6789

Covenant Children's Hospital, Lubbock, Texas

Status

Recruiting

Address

Covenant Children's Hospital

Lubbock, Texas, 79410

Site Contact

Site Public Contact

[email protected]

806-725-8657

UMC Cancer Center / UMC Health System, Lubbock, Texas

Status

Recruiting

Address

UMC Cancer Center / UMC Health System

Lubbock, Texas, 79415

Site Contact

Site Public Contact

806-775-8590

Children's Hospital of San Antonio, San Antonio, Texas

Status

Recruiting

Address

Children's Hospital of San Antonio

San Antonio, Texas, 78207

Site Contact

Site Public Contact

[email protected]

210-704-2894

San Antonio, Texas

Status

Recruiting

Address

Methodist Children's Hospital of South Texas

San Antonio, Texas, 78229

Site Contact

Site Public Contact

[email protected]

210-575-6240

San Antonio, Texas

Status

Recruiting

Address

University of Texas Health Science Center at San Antonio

San Antonio, Texas, 78229

Site Contact

Site Public Contact

[email protected]

210-450-3800

Primary Children's Hospital, Salt Lake City, Utah

Status

Recruiting

Address

Primary Children's Hospital

Salt Lake City, Utah, 84113

Site Contact

Site Public Contact

801-585-5270

University of Virginia Cancer Center, Charlottesville, Virginia

Status

Recruiting

Address

University of Virginia Cancer Center

Charlottesville, Virginia, 22908

Site Contact

Site Public Contact

[email protected]

434-243-6303

Seattle Children's Hospital, Seattle, Washington

Status

Recruiting

Address

Seattle Children's Hospital

Seattle, Washington, 98105

Site Contact

Site Public Contact

866-987-2000

Spokane, Washington

Status

Recruiting

Address

Providence Sacred Heart Medical Center and Children's Hospital

Spokane, Washington, 99204

Site Contact

Site Public Contact

[email protected]

800-228-6618

Tacoma, Washington

Status

Recruiting

Address

Mary Bridge Children's Hospital and Health Center

Tacoma, Washington, 98405

Site Contact

Site Public Contact

[email protected]

253-403-1461

Madison, Wisconsin

Status

Recruiting

Address

University of Wisconsin Carbone Cancer Center - University Hospital

Madison, Wisconsin, 53792

Site Contact

Site Public Contact

[email protected]

800-622-8922

Marshfield Medical Center-Marshfield, Marshfield, Wisconsin

Status

Suspended

Address

Marshfield Medical Center-Marshfield

Marshfield, Wisconsin, 54449

Children's Hospital of Wisconsin, Milwaukee, Wisconsin

Status

Recruiting

Address

Children's Hospital of Wisconsin

Milwaukee, Wisconsin, 53226

Site Contact

Site Public Contact

[email protected]

414-955-4727

International Sites

Sydney Children's Hospital, Randwick, New South Wales, Australia

Status

Recruiting

Address

Sydney Children's Hospital

Randwick, New South Wales, 2031

Site Contact

Site Public Contact

(02) 9382-1721

The Children's Hospital at Westmead, Westmead, New South Wales, Australia

Status

Recruiting

Address

The Children's Hospital at Westmead

Westmead, New South Wales, 2145

Site Contact

Site Public Contact

61-2-9845 1400

Queensland Children's Hospital, South Brisbane, Queensland, Australia

Status

Recruiting

Address

Queensland Children's Hospital

South Brisbane, Queensland, 4101

Site Contact

Site Public Contact

61 7 3068 1111

Perth Children's Hospital, Perth, Western Australia, Australia

Status

Recruiting

Address

Perth Children's Hospital

Perth, Western Australia, 6009

Site Contact

Site Public Contact

[email protected]

Alberta Children's Hospital, Calgary, Alberta, Canada

Status

Recruiting

Address

Alberta Children's Hospital

Calgary, Alberta, T3B 6A8

Site Contact

Site Public Contact

[email protected]

403-220-6898

University of Alberta Hospital, Edmonton, Alberta, Canada

Status

Recruiting

Address

University of Alberta Hospital

Edmonton, Alberta, T6G 2B7

Site Contact

Site Public Contact

[email protected]

780-407-8798

British Columbia Children's Hospital, Vancouver, British Columbia, Canada

Status

Recruiting

Address

British Columbia Children's Hospital

Vancouver, British Columbia, V6H 3V4

Site Contact

Site Public Contact

604-875-2345 #6477

CancerCare Manitoba, Winnipeg, Manitoba, Canada

Status

Recruiting

Address

CancerCare Manitoba

Winnipeg, Manitoba, R3E 0V9

Site Contact

Site Public Contact

[email protected]

866-561-1026

IWK Health Centre, Halifax, Nova Scotia, Canada

Status

Recruiting

Address

IWK Health Centre

Halifax, Nova Scotia, B3K 6R8

Site Contact

Site Public Contact

[email protected]

902-470-8520

Hamilton, Ontario, Canada

Status

Recruiting

Address

McMaster Children's Hospital at Hamilton Health Sciences

Hamilton, Ontario, L8N 3Z5

Site Contact

Site Public Contact

905-521-2100

Children's Hospital, London, Ontario, Canada

Status

Recruiting

Address

Children's Hospital

London, Ontario, N6A 5W9

Site Contact

Site Public Contact

519-685-8306

Hospital for Sick Children, Toronto, Ontario, Canada

Status

Recruiting

Address

Hospital for Sick Children

Toronto, Ontario, M5G 1X8

Site Contact

Site Public Contact

[email protected]

416-813-7654

Montreal, Quebec, Canada

Status

Recruiting

Address

The Montreal Children's Hospital of the MUHC

Montreal, Quebec, H3H 1P3

Site Contact

Site Public Contact

[email protected]

514-412-4445

Montreal, Quebec, Canada

Status

Recruiting

Address

Centre Hospitalier Universitaire Sainte-Justine

Montreal, Quebec, H3T 1C5

Site Contact

Site Public Contact

[email protected]

514-345-4931

Sherbrooke, Quebec, Canada

Status

Recruiting

Address

Centre Hospitalier Universitaire de Sherbrooke-Fleurimont

Sherbrooke, Quebec, J1H 5N4

Site Contact

Site Public Contact

[email protected]

819-820-6480

Jim Pattison Children's Hospital, Saskatoon, Saskatchewan, Canada

Status

Recruiting

Address

Jim Pattison Children's Hospital

Saskatoon, Saskatchewan, S7N 0W8

Site Contact

Site Public Contact

[email protected]

306-655-3544

Quebec, Canada

Status

Recruiting

Address

CHU de Quebec-Centre Hospitalier de l'Universite Laval (CHUL)

Quebec, , G1V 4G2

Site Contact

Site Public Contact

[email protected]

418-525-4444

Starship Children's Hospital, Grafton, Auckland, New Zealand

Status

Recruiting

Address

Starship Children's Hospital

Grafton, Auckland, 1145

Site Contact

Site Public Contact

0800 728 436

Clinical Trial Finder